|
|
CAF05 |
|
Vaxjo ID |
352 |
|
Vaccine Adjuvant Name |
CAF05 |
|
Adjuvant VO ID |
VO_0005576
|
|
Description |
cationic liposome adjuvant that induces a mixed Th1/Th17 response |
|
Stage of Development |
Research |
|
Location Licensed |
Denmark |
|
Host Species for Testing |
Mouse |
|
Components |
CAF01 incorporating the TLR3 ligand polyinosinic/polycytidylic acid [poly(I:C) |
|
Preparation |
Addition of poly(I:C)) to CAF01 was done stepwise in a manner to avoid aggregation of the CAF05 adjuvant |
|
Function |
induce high frequencies of antigen-specific cytotoxic CD8+ T cells and significantly reduce tumor growth |
| References |
Hansen et al., 2012: Hansen J, Lindenstrøm T, Lindberg-Levin J, Aagaard C, Andersen P, Agger EM. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice. Cancer immunology, immunotherapy : CII. 2012; 61(6); 893-903. [PubMed: 22095092].
|
|
